PWM
REGN icon

Parkworth Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Parkworth Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$2.1K Buy
4
+3
+300% +$1.67K ﹤0.01% 265
2025
Q1 		$634 Hold
1
– – ﹤0.01% 359
2024
Q4 		$712 Buy
+1
New +$839 ﹤0.01% 345

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Parkworth Wealth Management's REGN Position: Q2 2025 in Review

Parkworth Wealth Management increased its Regeneron Pharmaceuticals (REGN) stake by 300% in Q2 2025, buying an estimated $1.67K and bringing the position to 4 shares worth $2.1K. The position accounts for ﹤0.01% of the portfolio, ranked #265.

Parkworth Wealth Management first reported a position in REGN in Q4 2024 and has held it in 3 quarters since. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

  • Parkworth Wealth Management held 4 shares of Regeneron Pharmaceuticals worth $2.1K as of Q2 2025.
  • Parkworth Wealth Management bought 3 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $1.67K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Parkworth Wealth Management's portfolio in Q2 2025, its #265 holding.
  • Parkworth Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 3 quarters since.
  • 1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Parkworth Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.